Literature DB >> 7769110

Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

K E Balashov1, S J Khoury, D A Hafler, H L Weiner.   

Abstract

The autologous mixed lymphocyte reaction (AMLR) involves the activation of T cells by autologous antigen presenting cells. Cells are generated during the course of the AMLR that have suppressive properties in vitro. In the present study we investigated the induction of CD8+ T cells in the AMLR with suppressive properties and the mechanism by which these cells downregulate in vitro proliferative responses. Purified CD8+ but not CD4+ T cells activated in the AMLR in conditioned medium inhibited proliferation of autologous T cells by anti-CD3 or PPD. Nonactivated CD8+ T cells did not suppress. The CD8+ T cells activated in the AMLR in the presence of conditioned medium (CD8+ Tact) were CD11b negative and were noncytotoxic. The inhibitory effect of CD8+ Tact cells was completely abrogated by anti-IFN-gamma antibody, but not by anti-IL-4, anti-IL-10, or anti-TGF-beta antibody. The induction of CD8+ Tact cells in the AMLR was blocked by anti-IL-2 or by anti-GM-CSF antibody and the combination of these two recombinant cytokines could support the induction of suppressive CD8+ Tact cells. CD8+ Tact cells were defective in patients with chronic progressive multiple sclerosis (MS) as compared to patients with relapsing-remitting MS or normal controls. Our studies provide a basis for understanding the mechanism of suppression by human CD8+ T cells in terms of specific cytokines, and demonstrate the potential importance of these cells in a human autoimmune disease as their function is defective in patients with progressive MS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769110      PMCID: PMC295954          DOI: 10.1172/JCI117973

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones.

Authors:  J Koide; E G Engleman
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

Review 2.  T lymphocyte-derived colony-stimulating factors.

Authors:  A Kelso; D Metcalf
Journal:  Adv Immunol       Date:  1990       Impact factor: 3.543

3.  Decreased HLA-DR antigen expression on monocytes causes impaired suppressor cell activity in multiple sclerosis.

Authors:  C N Baxevanis; G J Reclos; M Papamichail
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

4.  Functional characterization of the CD45R (2H4) molecule on CD8 (T8) cells in the autologous mixed lymphocyte reaction system.

Authors:  T Takeuchi; C E Rudd; S Tanaka; D M Rothstein; S F Schlossman; C Morimoto
Journal:  Eur J Immunol       Date:  1989-04       Impact factor: 5.532

5.  Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats.

Authors:  J A Voorthuis; B M Uitdehaag; C J De Groot; P H Goede; P H van der Meide; C D Dijkstra
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

Review 6.  MS: a CNS and systemic autoimmune disease.

Authors:  D A Hafler; H L Weiner
Journal:  Immunol Today       Date:  1989-03

7.  Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.

Authors:  S Markowicz; E G Engleman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 8.  Antigen-specific suppressor T lymphocytes in man.

Authors:  N K Damle; E G Engleman
Journal:  Clin Immunol Immunopathol       Date:  1989-11

9.  Interleukin-2-induced production of interferon-gamma by resting human T cells and large granular lymphocytes: requirement for accessory cell factors, including interleukin-1.

Authors:  A B Wilson; J M Harris; R R Coombs
Journal:  Cell Immunol       Date:  1988-04-15       Impact factor: 4.868

10.  Exacerbations of multiple sclerosis in patients treated with gamma interferon.

Authors:  H S Panitch; R L Hirsch; A S Haley; K P Johnson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

View more
  25 in total

1.  Disproportionate recruitment of CD8+ T cells into the central nervous system by professional antigen-presenting cells.

Authors:  M J Carson; C R Reilly; J G Sutcliffe; D Lo
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 2.  Role of cytokines in the pathogenesis of autoimmune diabetes mellitus.

Authors:  Alex Rabinovitch; Wilma L Suarez-Pinzon
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis.

Authors:  Nathan R York; Jason P Mendoza; Sterling B Ortega; Andrew Benagh; Andrew F Tyler; Mihail Firan; Nitin J Karandikar
Journal:  J Autoimmun       Date:  2010-02-20       Impact factor: 7.094

4.  Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

Authors:  Khrishen Cunnusamy; Ethan J Baughman; Jorge Franco; Sterling B Ortega; Sushmita Sinha; Parul Chaudhary; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2014-03-20       Impact factor: 3.969

Review 5.  CD8(+) Tregs in autoimmunity: learning "self"-control from experience.

Authors:  Sue Tsai; Xavier Clemente-Casares; Pere Santamaria
Journal:  Cell Mol Life Sci       Date:  2011-06-14       Impact factor: 9.261

Review 6.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 7.  Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice.

Authors:  Brian J Skaggs; Ram Pyare Singh; Bevra H Hahn
Journal:  Hum Immunol       Date:  2008-09-24       Impact factor: 2.850

8.  Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.

Authors:  Hyun-Il Cho; Esteban Celis
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

9.  Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms.

Authors:  Mei-Ling Chen; Bo-Shiun Yan; Deneen Kozoriz; Howard L Weiner
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

10.  TGF-beta and IL-10 production by HIV-specific CD8+ T cells is regulated by CTLA-4 signaling on CD4+ T cells.

Authors:  Mohamed Elrefaei; Candace M Burke; Chris A R Baker; Norman G Jones; Stephanie Bousheri; David R Bangsberg; Huyen Cao
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.